The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine
Open accessAbstract
We recently reported that fluoxetine or paroxetine, two selective serotonin reuptake inhibitors (SSRIs), when administered to rats, increase the brain content of the neurosteroid 3α-hydroxy-5α-pregnane-20-one (3α5α-ALLO) without altering the brain content of other neurosteroids. ALLO (3α5α and 3α5β isomers) binds with high affinity to various γ-aminobutyric acid (GABA) receptor A subtypes and facilitates the action of GABA at these receptors. We hypothesized that the increase of ALLO brain content induced by treatment with SSRIs could contribute to alleviating the anxiety and dysphoria associated with the symptomatology of major unipolar depression. We measured ALLO content in four cisternal–lumbar fractions of cerebrospinal fluid (CSF) before and 8–10 weeks after treatment with fluoxetine or fluvoxamine in 15 patients with unipolar major depression. The concentration of ALLO (≈40 fmol/ml in each CSF fraction of three control subjects) was about 60% lower in patients with major unipolar depression. However, in the same patients, fluoxetine or fluvoxamine treatment normalized the CSF ALLO content. Moreover, a statistically significant correlation ( r = 0.58; P < 0.023; n = 15) existed between symptomatology improvement (Hamilton Rating Scale for Depression scores) and the increase in CSF ALLO after fluoxetine or fluvoxamine treatment. The CSF content of PREG and PROG remained unaltered after treatment and failed to correlate with the SSRI-induced increase of CSF ALLO. The normalization of CSF ALLO content in depressed patients appears to be sufficient to mediate the anxiolytic and antidysphoric actions of fluoxetine or fluvoxamine via its positive allosteric modulation of GABA type A receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paul, S. M., & Purdy, R. H. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.6.1347506 · Cited by 1,319
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Neurosteroids and GABAA receptor function
Lambert, J. J., Belelli, D., Hill-Venning, C., & Peters, J. A. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89058-6 · Cited by 746
Neurosteroids act on recombinant human GABAA receptors
Puia, G., Santi, M., Vicini, S., Pritchett, D. B., Purdy, R. H., Paul, S. M., Seeburg, P. H., & Costa, E. (1990) · Neuron · doi:10.1016/0896-6273(90)90202-q · Cited by 519
Self-citationFluoxetine in the Treatment of Premenstrual Dysphoria
Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., Grover, D., & Streiner, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322301 · Cited by 445
Barden, N., Reul, J. M. H. M., & Holsboer, F. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93942-q · Cited by 391
Paul, S. M., & Purdy, R. H. (1992) · PubMed · Cited by 384
Normington, K., & Russell, D. W. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41809-1 · Cited by 379
Progesterone metabolite allopregnanolone in women with premenstrual syndrome
RAPKIN, A., MORGAN, M., GOLDMAN, L., BRANN, D., SIMONE, D., & MAHESH, V (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00417-1 · Cited by 376
Wang, M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.1076 · Cited by 353
Cited by
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Neurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Neurosteroids: biosynthesis and function of these novel neuromodulators
Compagnone, N. A., & Mellon, S. H. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0188 · Cited by 820
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives
Rupprecht, R., & Holsboer, F. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01399-5 · Cited by 633
Li, S. H., & Graham, B. M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30358-3 · Cited by 579
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Neurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Role of GABA in anxiety and depression
Kalueff, A. V., & Nutt, D. J. (2007) · Depression and Anxiety · doi:10.1002/da.20262 · Cited by 534
Pathophysiological mechanisms implicated in postpartum depression
Payne, J. L., & Maguire, J. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.12.001 · Cited by 459
The role of reproductive hormones in postpartum depression
Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2015) · CNS Spectrums · doi:10.1017/s1092852914000480 · Cited by 451
GABAAR Plasticity during Pregnancy: Relevance to Postpartum Depression
Maguire, J., & Mody, I. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.019 · Cited by 437
Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties
Rupprecht, R. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00064-1 · Cited by 427
Concas, A., Mostallino, M. C., Porcu, P., Follesa, P., Barbaccia, M. L., Trabucchi, M., Purdy, R. H., Grisenti, P., & Biggio, G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13284 · Cited by 421
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Epperson, C. N., Haga, K., Mason, G. F., Sellers, E., Gueorguieva, R., Zhang, W., Weiss, E., Rothman, D. L., & Krystal, J. H. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.9.851 · Cited by 399
Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes
Griffin, L. D., & Mellon, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13512 · Cited by 387
Serra, M., Pisu, M. G., Littera, M., Papi, G., Sanna, E., Tuveri, F., Usala, L., Purdy, R. H., & Biggio, G. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750732.x · Cited by 315
Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
Zorumski, C. F., Paul, S. M., Covey, D. F., & Mennerick, S. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100196 · Cited by 305
VanDoren, M. J., Matthews, D. B., Janis, G. C., Grobin, A. C., Devaud, L. L., & Morrow, A. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01982.2000 · Cited by 313
The role of allopregnanolone in depression and anxiety
Schüle, C., Nothdurfter, C., & Rupprecht, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.003 · Cited by 312
Depression gets old fast: do stress and depression accelerate cell aging?
Wolkowitz, O. M., Epel, E. S., Reus, V. I., & Mellon, S. H. (2010) · Depression and Anxiety · doi:10.1002/da.20686 · Cited by 298
“Although circulating cortisol concentrations are frequently elevated in depression, plasma and CSF concentrations of the GABA-A receptor agonist neurosteroid, allopregnanolone, are decreased in unmedicated depressives, plasma and CSF levels of allopregnanolone increase with selective serotonin reuptake inhibitor (SSRI…”
BackgroundBiosynthesis and action of neurosteroids
Mellon, S. H., Griffin, L. D., & Compagnone, N. A. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00109-6 · Cited by 296
??-1 Receptor Ligands: Potential in the Treatment of Neuropsychiatric Disorders
Hayashi, T., & Su, T.-P. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00001 · Cited by 294
Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder
Rasmusson, A. M., Pinna, G., Paliwal, P., Weisman, D., Gottschalk, C., Charney, D., Krystal, J., & Guidotti, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.026 · Cited by 276
Self-citationTraish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02157.x · Cited by 275
Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder
Girdler, S. S., Straneva, P. A., Light, K. C., Pedersen, C. A., & Morrow, A. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01044-1 · Cited by 267
Dong, E., Matsumoto, K., Uzunova, V., Sugaya, I., Takahata, H., Nomura, H., Watanabe, H., Costa, E., & Guidotti, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628598 · Cited by 261
Self-citationSteroids, neuroactive steroids and neurosteroids in psychopathology
Dubrovsky, B. O. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.001 · Cited by 250
Pinna, G., Costa, E., & Guidotti, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0213-2 · Cited by 245
Self-citationTrial of SAGE-217 in Patients with Major Depressive Disorder
Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815981 · Cited by 232
Shirayama, Y., & Chaki, S. (2006) · Current Neuropharmacology · doi:10.2174/157015906778520773 · Cited by 225
Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors
Herd, M. B., Belelli, D., & Lambert, J. J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.007 · Cited by 206
Hantsoo, L., & Epperson, C. N. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100213 · Cited by 199
Evans, J., Sun, Y., McGregor, A., & Connor, B. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.012 · Cited by 184
Neurosteroids: Endogenous allosteric modulators of GABAA receptors
Lambert, J. J., Cooper, M. A., Simmons, R. D. J., Weir, C. J., & Belelli, D. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.08.009 · Cited by 180
Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study
Osborne, L. M., Gispen, F., Sanyal, A., Yenokyan, G., Meilman, S., & Payne, J. L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.012 · Cited by 175
Pinna, G., Costa, E., & Guidotti, A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.006 · Cited by 156
Self-citationGABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response
Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., & Belelli, D. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.06.001 · Cited by 149
Neurosteroids in the context of stress: implications for depressive disorders
Girdler, S. S., & Klatzkin, R. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.006 · Cited by 148
Locci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
The Role of HPA Axis and Allopregnanolone on the Neurobiology of Major Depressive Disorders and PTSD
Almeida, F. B., Pinna, G., & Barros, H. M. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115495 · Cited by 130
Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion
Wirth, M. M. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00019 · Cited by 121
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
Maguire, J. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00083 · Cited by 113
“, 2001) and there is a negative correlation between allopregnanolone levels and severity of depression symptoms (Uzunova et al., 1998; Nappi et al., 2001) (for review see Girdler and Klatzkin, 2007; Uzunova et al.”
BackgroundInfluentialAllopregnanolone-based treatments for postpartum depression: Why/how do they work?
Walton, N., & Maguire, J. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100198 · Cited by 103
Hormonal, cardiovascular, and subjective responses to acute stress in smokers
Childs, E., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1359-5 · Cited by 97
A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
Brown, E. S., Park, J., Marx, C. E., Hynan, L. S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., Lo, A., & Holmes, T. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.138 · Cited by 96
“This is perhaps in contrast to a study that found that CSF allopregnanolone increased during selective serotonin reuptake inhibitor therapy and that changes in allopregnanolone correlated with improvement in depressive symptoms (Uzunova et al, 1998).”
ResultNeurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders
Ratner, M. H., Kumaresan, V., & Farb, D. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00169 · Cited by 96
Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain
Kishimoto, W., Hiroi, T., Shiraishi, M., Osada, M., Imaoka, S., Kominami, S., Igarashi, T., & Funae, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1109 · Cited by 90
“fluoxetine, which increased the level of allopregnanolone in the brain of rats (37) and humans (38).”
BackgroundSze, Y., & Brunton, P. J. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14615 · Cited by 85
Hardoy, M. C., Serra, M., Carta, M. G., Contu, P., Pisu, M. G., & Biggio, G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000229483.52955.ec · Cited by 80
“Consistent with our findings, the plasmatic concentration of neuroactive steroids was increased after 8 to 10 weeks of treatment with fluoxetine or fluvoxamine, and this effect was proportional to the treatmentinduced increase in score on the Hamilton Rating Scale for Depression.23 In the present study, drug-free and…”
ResultRealising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
Belelli, D., Hogenkamp, D., Gee, K. W., & Lambert, J. J. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100207 · Cited by 67
Sripada, R. K., Welsh, R. C., Marx, C. E., & Liberzon, I. (2014) · Human Brain Mapping · doi:10.1002/hbm.22399 · Cited by 66
Raber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
Almeida, F. B., Barros, H. M. T., & Pinna, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041758 · Cited by 57
“These GABAergic steroids are found diminished in the cerebrospinal fluid (CSF) [11], serum [12], and plasma [13] of depressed individuals.”
BackgroundTargeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Locci, A., Geoffroy, P., Miesch, M., Mensah-Nyagan, A.-G., & Pinna, G. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00208 · Cited by 52
Dichtel, L. E., Nyer, M., Dording, C., Fisher, L. B., Cusin, C., Shapero, B. G., Pedrelli, P., Kimball, A. S., Rao, E. M., Mischoulon, D., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12887 · Cited by 40
Hypothesis: The Role of Sterols in Autism Spectrum Disorder
Lee, R. W. Y., & Tierney, E. (2011) · Autism Research and Treatment · doi:10.1155/2011/653570 · Cited by 30
Neurosteroids and neuropathic pain management: Basic evidence and therapeutic perspectives
Meyer, L., Taleb, O., Patte-Mensah, C., & Mensah-Nyagan, A.-G. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100795 · Cited by 30
Allopregnanolone (1938–2019): A trajectory of 80 years of outstanding scientific achievements
Pinna, G. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100246 · Cited by 24
Koonce, C. J., & Frye, C. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.07.025 · Cited by 23
Berretti, R., Santoru, F., Locci, A., Sogliano, C., Calza, A., Choleris, E., Porcu, P., & Concas, A. (2014) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.12.009 · Cited by 17
Espallergues, J., Temsamani, J., Laruelle, C., Urani, A., & Maurice, T. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2053-y · Cited by 8
“1996) and normalized the cerebrospinal fluid content in allopregnanolone after 8– 10 weeks treatment with fluoxetine or fluvoxamine (Uzunova et al. 1998), suggesting that activation of the 3αhydroxysteroid oxydoreductase is a necessary step for the behavioral efficacy of the antidepressants.”
Background
Metadata
- Authors
- Uzunova, V., Sheline, Y., Davis, J. M., Rasmusson, A., Uzunov, D. P., Costa, E., & Guidotti, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-03-17
- Volume
- 95
- Issue
- 6
- Pages
- 3239-3244
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2127483997
- Cited by
- 672
- References
- 23
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.